

BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

MARCATORI DI DANNO CARDIACO RADIOINDOTTO IN PAZIENTI CON MALATTIA DELLA MAMMELLA IN STADIO INIZIALE TRATTATE CON RADIOTERAPIA ADIUVANTE: UN TRIAL PROSPETTICO

R. Mazzola, G. Lunardi, E. Pastorello, M. Fiorini, N. Giaj Levra, L. Nicosia, M. Rigo, F. Ricchetti, A. Allegra, G. Sicignano, A. De Simone, D. Gurrera, S. Naccarato, R. Ruggieri, F. Alongi

> Dipartimento Radioterapia Oncologica Avanzata IRCCS, Sacro Cuore Don Calabria Negrar di Valpolicella



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

RADIATION-INDUCED HEART DISEASE Lessons from the past in the era of "modern" radiation therapy

The NEW ENGLAND JOURNAL of MEDICINE ESTABLISHED IN 1812 MARCH 14, 2013 VOL 368 NO 11 Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer 200 ົວ Sarah C. Darby, Ph.D., Marianne Ewertz, D.M.Sc., Paul McGale, Ph.D., Anna M. Bennet, Ph.D., Ulla Blom-Goldman, M.D., Dorthe Brønnum, R.N., Candace Correa, M.D., David Cutter, F.R.C.R., %56) Giovanna Gagliardi, Ph.D., Bruna Gigante, Ph.D., Maj-Britt Jensen, M.Sc., Andrew Nisbet, Ph.D., Richard Peto, F.R.S., Kazem Rahimi, D.M., Carolyn Taylor, D.Phil., and Per Hall, Ph.D. 150-Events Figure 1. Rate of Major Coronary Events According to Mean Radiation Dose to the Heart, as Compared with the ease in Rate of Major Coronary 100-Estimated Rate with No Radiation Exposure to the Heart. Major coronary events included myocardial infarction, coronary revascularization, and death from ischemic heart disease. The values for the solid line were calculat-50 ed with the use of dose estimates for individual women. The circles show values for groups of women, classified according to dose categories; the associated vertical lines represent 95% confidence intervals. All estimates were calculated after stratification for country and for age at breast-cancer diagnosis, year of breast-cancer diagnosis, interval between breast-cancer diagnosis and first major coronary event for case patients or index date for cent Incre -50controls (all in 5-year categories), and presence or absence of a cardiac risk factor. The radiation categories Increase per gray, 7.4% (95% CI, 2.9-14.5) were less than 2, 2 to 4, 5 to 9, and 10 Gy or more, and P<0.001 the overall averages of the mean doses to the heart of å -100women in these categories were 1.4, 3.4, 6.5, and 15.8 Gy, respectively. 0 2 4 8 10 12 14 16 18 20

BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI



Mean Dose of Radiation to Heart (Gy)



Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

RADIATION-INDUCED HEART DISEASE Lessons from the past in the era of "modern" radiation therapy





AIRO2023

STUDY Design

Pilot study, non-profit, prospective single-center (Ethical Committee approval 06/2019)

STUDY Objectives

To assess any alterations in cardiac function before and after radiotherapy (end of radiation treatment, at 6 and 12 months) by means of

 Biochemical parameters (high sensitivity myocardial troponin I and N-terminal pro-BNP)
Instrumental parameters (echo-cardiogram with evaluation of ejection fraction and GLSglobal longitudinal strand or longitudinal deformation)



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Population of study

Inclusion criteria

- Age ≥18 years
- Breast cancer subtypes Luminal A or Luminal B not candidates for chemotherapy and/or target therapy
- Conservative surgery with negative or close margins
- Stage pT1-2 pN0-N1 Absence of distant metastases (M0)
- Karnofsky status > 70
- Signature of specific informed consent

Exclusion criteria

- Pregnancy
- **Positive history of cardiovascular diseases** (previous acute myocardial infarction, coronary syndrome, congenital or acquired cardiomyopathy, rhythm disorders)





Methods

- **Sample size:** 60 pts (30 left side and 30 right side)
- □ **RT details:** whole breast with SIB (SIB for age > 60y) IMRT 3/4-fields conventional fractionation
- □ Statistical analysis: Correlation between heart d-mean and left anterior descending (LAD) coronary artery d-mean with:
- 1. Troponin I high sensitivity
- 2. N-terminal pro-BNP
- 3. LVEF-left ventricular ejection fraction
- 4. GLS-global longitudinal strand



AIRO2023

Results (1)

- ✓ Median age was 54 years old (range, 35-77) for entire sample size
- ✓ 33 patients affected by left side BC (30 pT1pN0; 4 pT2pN0, Luminal A)
- ✓ 30 patients affected by right side BC were analyzed (26 pT1pN0; 5 pT2pN0, Luminal A)

Baseline dosimetric parameters	LEFT SIDE BC	RIGHT SIDE BC	P-value
Heart mean dose	1.8Gy (range, 0.1-8Gy)	0.69Gy (range, 0.05-3.9 Gy)	0.007
LAD mean dose	2.5Gy (range, 0-17Gy)	0.14Gy (range, 0-21Gy)	0.003

Patients were stratified at the 75th percentile for dosimetric variables Heart mean dose < or > 1.9 Gy *and* LAD mean dose < or > 3.9 Gy



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Results (2): Troponin I

Patients were stratified at the 75th percentile for dosimetric variables Heart mean dose < or > 1.9 Gy and LAD mean dose < or > 3.9 Gy

At baseline non statistically significance of Troponin I levels according to stratification (p-value 0.17 and 0.37, respectively)

There was an increase of troponin I high sensitivity values at the end of RT (Δ pre- and post-RT 1.16 ng/L) with a subsequent recovery at 6 and 12 months post-RT for patients with heart d-mean > 1.9Gy (p-value < 0.5)





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Results (3): N-terminal Pro-BNP

Patients were stratified at the 75th percentile for dosimetric variables Heart mean dose < or > 1.9 Gy and LAD mean dose < or > 3.9 Gy

At baseline non statistically significance of N-terminal Pro-BNP levels according to stratification (p-value 0.19 and 0.23, respectively)

There was a statistically significant increase of N-terminal Pro-BNP lately, at 6 AND 12 months, post-RT (p-value < 0.07 and 0.00, respectively) for dmean LAD > 3.9Gy





Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Results (4): ecocardiographic parameters

Patients were stratified at the 75th percentile for dosimetric variables Heart mean dose < or > 1.9 Gy and LAD mean dose < or > 3.9 Gy

At baseline non statistically significance regarding LVEF-left ventricular ejection fraction and GLS-global longitudinal strand according to dosimetric stratification criteria

Regarding the ecocardiographic parameters here analyzed, there was a 2% LVEF reduction at the end of RT for LAD d-mean > 3.9Gy (p-value 0.008; range, +8%/-10%) with a subsequent recovery over the time of follow up

No statistically significance regarding GLS-variable variation over time





CONCLUSION

□ In the case of heart d-mean > 1.9Gy it was observed an acute cardiac damage documented by increased levels of Troponin I

□ In the case of LAD d-mean> 3.9Gy it was observed a ventricular dysfunction documented by increased levels of pro-BNP (lately) and 2% LVEF reduction at the end of RT

□ Long-term results are awaited to understand the clinical risk of cardiac events

